Sökning: onr:"swepub:oai:DiVA.org:uu-233796" >
Different impact of...
Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT : a long-term retrospective analysis from a single institution
-
- Nahi, H (författare)
- Karolinska Institutet
-
- Remberger, M (författare)
- Karolinska Institutet
-
- Machaczka, M (författare)
- Karolinska Institutet
-
visa fler...
-
- Ungerstedt, J (författare)
- Karolinska Institutet
-
- Mattson, J (författare)
- Karolinska Institutet
-
- Ringden, O (författare)
- Karolinska Institutet
-
Le-Blanc, Katarina (författare)
-
- Ljungman, P (författare)
- Karolinska Institutet
-
- Hägglund, Hans (författare)
- Division of Haematology, Department of Medicine, Karolinska Institutet Huddinge and Haematology Centre Karolinska, Karolinska University Hospital Huddinge, Stockholm, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2012-01-11
- 2012
- Engelska.
-
Ingår i: Medical Oncology. - : Springer Science and Business Media LLC. - 1357-0560 .- 1559-131X. ; 29:4, s. 2348-2358
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Karyotype of myeloblasts at the time of AML diagnosis has been shown to be prognostic significant for pre-remission outcome and outcome after allo-SCT, but the latter requires further studies. We conducted a retrospective analysis of the impact of intermediate and unfavourable cytogenetics at the time of primary diagnosis on outcome after allo-SCT in de novo AML. The study included 169 patients who underwent allo-SCT at Karolinska University Hospital between 1980 and 2010. Intermediate and unfavourable cytogenetics were found in 129 (76%) and 40 patients (24%), respectively. Myeloablative and reduced-intensity conditioning were given to 120 (71%) and 49 (29%) patients, respectively. Allo-SCT was performed in CR1 in 122 patients (72%). TRM was 16% in both cytogenetics groups. Relapse occurred in 29% patients with intermediate and in 45% patients with unfavourable cytogenetics (P=0.01). The probabilities of 5-year OS for patients with intermediate and unfavourable cytogenetics were 60 and 43%, respectively (P=0.02). Multivariate analysis revealed intermediate cytogenetics, chronic GVHD, and recipient CMV-negative serostatus as variables associated with favourable OS. Our study showed that outcome after allo-SCT in de novo AML differs depending on cytogenetic risk-group; however its position in post-remission therapy of eligible AML patients is not threatened.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas